Overview
From Diagnosis to Treatment: The Evolution of SSc-ILD
ILD eNewsletter
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this 45-minute multi-media eNewsletter, Dr. Ganesh Raghu discusses challenges in making a diagnosis of SSc-ILD, reviews current and emerging treatments, and discusses the importance of shared decision making and patient quality of life. Furthermore, perspectives from patient ambassadors will also be included, highlighting their journey and the complexities of diagnosis, treatment, and quality of life.
This activity is intended for pulmonologists, rheumatologists, internal medicine clinicians, and other healthcare clinicians (MD’s, PAs, and NPs) interested in treating patients with SSc-ILD.
Explore this 45-minute multi-media eNewsletter that will advance your understanding of systemic sclerosis interstitial lung disease (SSc-ILD) with Dr. Ganesh Raghu, Director of the University of Washington Interstitial Lung Disease/Sarcoid/Pulmonary Fibrosis Program.
While there have been significant advances in our understanding of SSc-ILD, there are important unmet needs that still must be addressed. These include improvements in the differential diagnosis, advances in therapy, appropriate application of pharmacotherapy, and communicating with patients to improve quality of life, which will be addressed in this activity. Perspectives from patient ambassadors are also included, highlighting their journey and the complexities of diagnosis, treatment, and quality of life.
While there have been significant advances in our understanding of SSc-ILD, there are important unmet needs that still must be addressed. These include improvements in the differential diagnosis, advances in therapy, appropriate application of pharmacotherapy, and communicating with patients to improve quality of life, which will be addressed in this activity. Perspectives from patient ambassadors are also included, highlighting their journey and the complexities of diagnosis, treatment, and quality of life.
After participating in this activity, the learner should be able to:
• Discuss the presentation, disease course, and prognosis of lung involvement in SSc
• Outline the integration of patient, clinical, and radiographic findings into a diagnosis of SSc-ILD
• Evaluate the efficacy and safety data of current and investigational therapies for the treatment of SSc-ILD
• Factor the needs of SSc-ILD patients into disease management
• Discuss the presentation, disease course, and prognosis of lung involvement in SSc
• Outline the integration of patient, clinical, and radiographic findings into a diagnosis of SSc-ILD
• Evaluate the efficacy and safety data of current and investigational therapies for the treatment of SSc-ILD
• Factor the needs of SSc-ILD patients into disease management
Sponsored by the Academy for Continued Healthcare Learning
The following financial relationships have been provided:
Patient A
Speaker and Honorarium Recipient: Boehringer Ingelheim Pharmaceuticals, Inc.
Patient B has nothing to disclose.
Ganesh Raghu, MD, FCCP, FACP
Professor of Medicine and Laboratory Medicine
Division of Pulmonary, Sleep & Critical Care Medicine
University of Washington
Director: Center for Interstitial Lung Diseases
Co-Director: Scleroderma Clinic
University of Washington Medical Center
Seattle, WA
This activity also featured two patients living with SSc-ILD: Patient A and Patient B
Professor of Medicine and Laboratory Medicine
Division of Pulmonary, Sleep & Critical Care Medicine
University of Washington
Director: Center for Interstitial Lung Diseases
Co-Director: Scleroderma Clinic
University of Washington Medical Center
Seattle, WA
This activity also featured two patients living with SSc-ILD: Patient A and Patient B
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Ganesh Raghu, MD, FCCP, FACP
Consulting: Boehringer Ingelheim Pharmaceuticals, Inc. and Roche-Genentech
Consulting: Boehringer Ingelheim Pharmaceuticals, Inc. and Roche-Genentech
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: agents under investigation for SSc-ILD
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.